Products
PlantForm's first product will be a subsequent-entry-biologic (SEB) version of the breast-cancer drug Herceptin, the brand name for trastuzumab.
Treatment with Herceptin can cost as much as $100,000 per patient per year.
Our SEB trastuzumab demonstrates equivalent purity and activity, and lowers manufacturing costs by as much as 90 per cent.
Herceptin sales ($5.7 billion in 2010) are forecast to grow a minimum of 8 per cent a year. Herceptin begins to lose patent protection in world markets in 2014. The accessible market for PlantForm's SEB trastuzumab is estimated to be $2 billion a year by 2016 and a minimum of $4 billion a year by 2020.
We will also use our production platform to produce SEB versions of other antibody drugs that, together with Herceptin, are forecast to have annual global sales in excess of $40 billion by 2013.
Our activity analysis demonstrates that the PlantForm SEB drug has the same efficacy as the name brand drug. Analysis is by in vitro breast cancer cell line growth inhibition assay in a laboratory test.